Peptides 101

LL-37: The Peptide Your Skin Has Been Making All Along

LL-37 is not a foreign compound. It is part of your body’s first line of defense. PeptideMatch.io examines the science behind this naturally occurring antimicrobial peptide and what the research says about its broader roles in immunity and tissue repair.

Close-up photo of man washing his hands at a bathroom sink.

LEGAL & MEDICAL DISCLAIMER: The information provided on this page by PeptideMatch.io is intended solely for educational and informational purposes. It does not constitute, and should not be interpreted as, professional medical advice, diagnosis, or treatment. Always consult a licensed physician or qualified healthcare provider before beginning any peptide therapy or making changes to an existing treatment plan. PeptideMatch.io does not prescribe, dispense, or endorse any specific therapeutic protocol. Individual results may vary, and no outcomes are guaranteed.

What is LL-37?

Your body does not wait for a doctor to fight infection. The moment a wound opens or a pathogen lands on the skin, a rapid-response system activates. LL-37 is one of the key players in that system.

LL-37 is a 37-amino acid peptide that belongs to a family called cathelicidins. This family of antimicrobial peptides is found in mammals, birds, fish, and reptiles. It’s the only cathelicidin found in humans. The body produces it in skin cells, white blood cells, lung tissue, and the gut lining, releasing it in response to injury, infection, or inflammation. Its name comes from its starting amino acids (two leucines, “LL”) and its 37-residue length.¹

What makes LL-37 interesting from a research standpoint is that it does not do just one thing. It kills bacteria directly by breaking apart their outer membranes. It also signals the immune system, promotes new blood vessel growth, and plays a role in wound closure. This range of activity has made it a focus of research in wound healing, skin conditions, and immune function.²

Fast Facts

FULL NAME	LL-37 (human cathelicidin antimicrobial peptide; hCAP18/LL-37)
CLASS	Antimicrobial peptide; cathelicidin family; host defense peptide
PRIMARY ACTION	Direct antimicrobial activity, immune cell signaling, blood vessel formation, and wound healing support
ADMINISTRATION	Investigational; studied in topical and injectable forms in research settings
RESEARCH	Preclinical and early clinical; active investigation in wound healing, skin conditions (rosacea, psoriasis), antimicrobial defense, and immune modulation
REGULATORY STATUS	Not FDA-approved for human therapeutic use; classified as a research compound

How Does LL-37 Work?

LL-37 works through several different pathways at once. This is what makes it unusual compared to most compounds studied in peptide research, which tend to work through a single receptor or mechanism.

1. Direct Antimicrobial Activity

LL-37 is positively charged, which allows it to be drawn toward the negatively charged outer membranes of bacteria. Once it reaches the bacterial surface, it inserts itself into the membrane and disrupts its structure, causing the bacteria to lose integrity and die. This mechanism works against a broad range of bacteria, including some strains that have developed resistance to traditional antibiotics. LL-37 has also shown activity against certain viruses and fungi in preclinical research.¹

2. Immune System Signaling

Beyond killing pathogens directly, LL-37 acts as a signal to the immune system. It recruits immune cells to the site of infection or injury, activates certain white blood cells, and helps coordinate the inflammatory response. Research has also found that it can reduce excessive inflammation in some contexts, suggesting a regulatory role rather than purely a pro-inflammatory one.²

3. New Blood Vessel Growth

LL-37 has been associated with the growth of new blood vessels, a process called angiogenesis, which is a necessary step in tissue repair. It also promotes the migration of skin cells (keratinocytes) across a wound, which is how the skin closes after injury. A 2003 study published in the Journal of Clinical Investigation demonstrated this angiogenic role and helped establish LL-37 as a candidate of interest in wound healing research.³

What Does the Research Say?

The research on LL-37 spans more than two decades. Most of the foundational work is in preclinical models and mechanistic studies, which look at the how and why behind processes. More recent research has begun to explore its potential in clinical contexts, particularly wound healing and skin conditions. PeptideMatch.io presents only what the peer-reviewed literature actually shows and where the evidence is limited.

The overall picture from the literature is that LL-37 is a well-characterized component of the body’s natural defense system. Its antimicrobial and immune-signaling roles are supported by a substantial body of research. Its potential as a therapeutic compound in wound healing and skin conditions is supported by preclinical research and early clinical interest, but large-scale clinical trial evidence is limited.

Wound healing is one of the most studied potential applications of LL-37. The reason comes down to the biology of how wounds close. Effective healing requires three things to happen in sequence: the wound must be protected from infection, new tissue must be built, and new blood vessels must grow into the healing area to deliver oxygen and nutrients. LL-37 has been associated with all three of these steps in research settings.

THERAPEUTIC AREA	WHAT RESEARCH SUGGESTS	EVIDENCE LEVEL
Infection Control	LL-37 is released at wound sites and has been associated with direct killing of bacteria that commonly infect open wounds, including some antibiotic-resistant strains, in preclinical research.¹	Preclinical
Keratinocyte Migration	Research has found that LL-37 promotes the movement of keratinocytes, the main cells of the outer skin layer, across wound surfaces. This is a key step in re-closing the skin after injury.²	Preclinical
New Blood Vessel Growth	LL-37 has been associated with angiogenesis in wound models, which supports the delivery of oxygen and nutrients to healing tissue and is considered a necessary part of full tissue repair.³	Preclinical

Researchers have noted that patients with chronic non-healing wounds, such as diabetic foot ulcers, often show reduced levels of LL-37 at wound sites compared to patients with normal healing. This observation has driven interest in whether supplementing LL-37 activity could support healing in these difficult clinical situations, though large-scale human trials have not yet established this as a proven approach.

Safety Profile

Because LL-37 is a naturally occurring peptide that the body already produces, its general tolerability profile in research settings has been considered favorable compared to many synthetic compounds. However, it is not approved for therapeutic use, and its safety in humans as an administered compound has not been formally established through large-scale clinical trials.

Important Considerations

Inflammatory Conditions	LL-37 is elevated in certain inflammatory skin conditions such as rosacea and psoriasis. Its role in these conditions is complex, and its use in individuals with active inflammatory skin disease requires careful medical evaluation.
Cancer Research Context	Research has found that LL-37 levels are altered in various cancers, with some studies finding elevated levels in certain tumor types. Its relationship to cell proliferation is an active area of investigation. Use in the context of active malignancy requires careful medical assessment.
Immune Modulation	Because LL-37 influences immune cell activity, its effects in individuals with autoimmune conditions or those on immunosuppressive therapy are not fully characterized.
Not FDA Approved	LL-37 is not approved for human therapeutic use by the FDA. It is a research compound.
Medical Oversight	Always work with a licensed healthcare provider before considering peptide therapy.

The Bottom Line: LL-37 occupies a unique place in peptide research. Unlike most compounds in this space, it’s not a synthetic molecule designed to mimic something the body does. It’s something the body already makes, and the research interest in it comes from a better understanding of what it actually does in human biology.
The evidence for its antimicrobial and immune-signaling roles is well-established at the mechanistic level. Preclinical data and early research supports its potential in wound healing and skin repair, and clinical investigation is ongoing. What is not yet available is the large-scale human trial evidence that would establish it as a proven therapeutic compound.
As with any research-stage compound, anyone considering LL-37 should work with a qualified healthcare provider who can assess individual health status, review the current state of the evidence, and provide appropriate medical oversight.

Scientific References

Bucki R, Leszczynska K, Namiot A, Sokolowski W. Cathelicidin LL-37: a multitask antimicrobial peptide. Arch Immunol Ther Exp (Warsz). 2010;58(1):15-25. doi:10.1007/s00005-009-0057-2
Mookherjee N, Anderson MA, Haagsman HP, Davidson DJ. Antimicrobial host defence peptides: functions and clinical potential. Nat Rev Drug Discov. 2020;19(5):311-332. doi:10.1038/s41573-019-0058-8
Koczulla R, von Degenfeld G, Kupatt C, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest. 2003;111(11):1665-1672. doi:10.1172/JCI17545

©2026 PeptideMatch.io. All Rights Reserved. This educational content is the exclusive intellectual property of PeptideMatch.io. Reproduction, distribution, republication, or transmission of this material, in whole or in part, in any form or by any means, is strictly prohibited without the prior written consent of PeptideMatch.io. For licensing or reprint inquiries, please contact content@peptidematch.io.